Suzhou Ribo Life Science Co., Ltd. and Ribocure AB have joined forces with Boehringer Ingelheim in a strategic collaboration aimed at pioneering novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). 

The partnership merges Ribo's extensive expertise in discovering and clinically developing small interfering RNA (siRNA) therapeutics with Boehringer's dedication to enhancing the lives of individuals grappling with cardiovascular, renal, and metabolic diseases (CRM).

With over 440 million people worldwide estimated to live with NASH, an inflammatory liver disease triggered by fat accumulation, the collaboration addresses a pressing need for effective treatment options. 

NASH, over time, leads to scar tissue formation and, in many cases, results in severe complications such as liver cirrhosis, liver failure, or liver cancer. Currently, there are no approved medicines for NASH, emphasizing the urgency for new therapies to prevent progression and restore liver function.

Ribo's RIBO-GalSTAR™ platform facilitates the development of RNA interference (RNAi) therapeutics targeting disease-causing genes specifically in hepatocytes by silencing their messenger RNAs (mRNAs). This approach holds promise in treating diseases by addressing previously inaccessible drug targets.

Søren Tullin, Ph.D., Senior Vice President and Global Head of Cardiometabolic Diseases Research at Boehringer Ingelheim, expressed anticipation for the collaboration, stating, "We look forward to working with the scientists from Ribo to develop new breakthrough medicines for patients with NASH. This new partnership is part of our commitment to collaborate with peers worldwide to address the interconnected nature of CRM diseases."

Zicai Liang, CEO of Ribo Life Sciences, highlighted the collaboration as a strong endorsement of Ribo's platform, expressing pleasure at the opportunity to work with Boehringer Ingelheim in developing solutions for people living with NASH.

Under the terms of the agreement, Ribo will receive an upfront payment and is entitled to success-based milestones for clinical, regulatory, and commercial achievements, along with tiered royalties. The overall deal value exceeds USD 2 billion.